BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 22902364)

  • 1. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma.
    Bianchi G; Kyle RA; Larson DR; Witzig TE; Kumar S; Dispenzieri A; Morice WG; Rajkumar SV
    Leukemia; 2013 Mar; 27(3):680-5. PubMed ID: 22902364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression.
    Gonsalves WI; Rajkumar SV; Dispenzieri A; Dingli D; Timm MM; Morice WG; Lacy MQ; Buadi FK; Go RS; Leung N; Kapoor P; Hayman SR; Lust JA; Russell SJ; Zeldenrust SR; Hwa L; Kourelis TV; Kyle RA; Gertz MA; Kumar SK
    Leukemia; 2017 Jan; 31(1):130-135. PubMed ID: 27457702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics.
    Vagnoni D; Travaglini F; Pezzoni V; Ruggieri M; Bigazzi C; Dalsass A; Mestichelli F; Troiani E; Falcioni S; Mazzotta S; Natale A; Angelini M; Ferretti S; Angelini S; Galieni P
    Br J Haematol; 2015 Aug; 170(4):523-31. PubMed ID: 26010293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma.
    Nowakowski GS; Witzig TE; Dingli D; Tracz MJ; Gertz MA; Lacy MQ; Lust JA; Dispenzieri A; Greipp PR; Kyle RA; Rajkumar SV
    Blood; 2005 Oct; 106(7):2276-9. PubMed ID: 15961515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders.
    Foulk B; Schaffer M; Gross S; Rao C; Smirnov D; Connelly MC; Chaturvedi S; Reddy M; Brittingham G; Mata M; Repollet M; Rojas C; Auclair D; DeRome M; ; Weiss B; Sasser AK
    Br J Haematol; 2018 Jan; 180(1):71-81. PubMed ID: 29105742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding high-risk smoldering multiple myeloma.
    Kreiniz N; Gertz MA
    Leuk Lymphoma; 2023; 64(8):1361-1372. PubMed ID: 37229535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.
    Dispenzieri A; Kyle RA; Katzmann JA; Therneau TM; Larson D; Benson J; Clark RJ; Melton LJ; Gertz MA; Kumar SK; Fonseca R; Jelinek DF; Rajkumar SV
    Blood; 2008 Jan; 111(2):785-9. PubMed ID: 17942755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance.
    Kumar S; Rajkumar SV; Kyle RA; Lacy MQ; Dispenzieri A; Fonseca R; Lust JA; Gertz MA; Greipp PR; Witzig TE
    J Clin Oncol; 2005 Aug; 23(24):5668-74. PubMed ID: 16110026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smoldering multiple myeloma: natural history and recognition of an evolving type.
    Rosiñol L; Bladé J; Esteve J; Aymerich M; Rozman M; Montoto S; Giné E; Nadal E; Filella X; Queralt R; Carrió A; Montserrat E
    Br J Haematol; 2003 Nov; 123(4):631-6. PubMed ID: 14616966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
    Bujarski S; Goldwater MS; Regidor BS; Jew S; Daniely D; Swift RA; Eades BM; Emamy-Sadr M; Souther E; Li M; Wang C; Xu N; Chen H; Spektor TM; Berenson JR
    Eur J Haematol; 2021 Sep; 107(3):318-323. PubMed ID: 33993536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow angiogenesis and circulating plasma cells in multiple myeloma.
    Kumar S; Witzig TE; Greipp PR; Rajkumar SV
    Br J Haematol; 2003 Jul; 122(2):272-4. PubMed ID: 12846897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form.
    Rago A; Grammatico S; Za T; Levi A; Mecarocci S; Siniscalchi A; De Rosa L; Felici S; Bongarzoni V; Piccioni AL; La Verde G; Pisani F; Franceschini L; Paviglianiti AL; Caravita T; Petrucci MT; De Stefano V; Cimino G;
    Cancer; 2012 Nov; 118(22):5544-9. PubMed ID: 22786730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma.
    Ravi P; Kumar S; Larsen JT; Gonsalves W; Buadi F; Lacy MQ; Go R; Dispenzieri A; Kapoor P; Lust JA; Dingli D; Lin Y; Russell SJ; Leung N; Gertz MA; Kyle RA; Bergsagel PL; Rajkumar SV
    Blood Cancer J; 2016 Jul; 6(7):e454. PubMed ID: 27471870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients.
    Henriot B; Rouger E; Rousseau C; Escoffre M; Sébillot M; Bendavid C; Minvielle S; Avet-Loiseau H; Decaux O; Moreau C
    Clin Chem Lab Med; 2019 Aug; 57(9):1397-1405. PubMed ID: 30973821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma.
    Han W; Jin Y; Xu M; Zhao SS; Shi Q; Qu X; Zhang R; Li J; Wu Y; Chen L
    Hematology; 2021 Dec; 26(1):510-517. PubMed ID: 34314294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adhesion molecule immunophenotype of bone marrow multiple myeloma plasma cells impacts the presence of malignant circulating plasma cells in peripheral blood.
    Klimienė I; Radzevičius M; Matuzevičienė R; Sinkevič-Belliot K; Kučinskienė ZA; Pečeliūnas V
    Int J Lab Hematol; 2021 Jun; 43(3):403-408. PubMed ID: 33185981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma.
    Witzig TE; Kyle RA; O'Fallon WM; Greipp PR
    Br J Haematol; 1994 Jun; 87(2):266-72. PubMed ID: 7947266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
    J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation.
    Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Haematologica; 2017 Aug; 102(8):1439-1445. PubMed ID: 28473618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.
    Pérez-Persona E; Vidriales MB; Mateo G; García-Sanz R; Mateos MV; de Coca AG; Galende J; Martín-Nuñez G; Alonso JM; de Las Heras N; Hernández JM; Martín A; López-Berges C; Orfao A; San Miguel JF
    Blood; 2007 Oct; 110(7):2586-92. PubMed ID: 17576818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.